Edition:
United States

Hemispherx Biopharma Inc (HEB)

HEB on American Stock Exchange

0.53USD
22 May 2017
Change (% chg)

$0.00 (+0.15%)
Prev Close
$0.53
Open
$0.53
Day's High
$0.54
Day's Low
$0.51
Volume
53,100
Avg. Vol
285,661
52-wk High
$2.64
52-wk Low
$0.39

Summary

Name Age Since Current Position

William Mitchell

81 2016 Chairman of the Board

Thomas Equels

64 2016 Executive Vice Chairman, Chief Executive Officer, President, Secretary, & General Counsel

Adam Pascale

68 2016 Chief Financial Officer

Wayne Springate

45 2011 Senior Vice President - Operations

David Strayer

70 2016 Chief Scientific & Medical Officer

Peter Rodino

65 2016 Executive Director - Governmental Relations, General Counsel

Stewart Appelrouth

2016 Director

Charles Jones

2012 Investor Relations

Biographies

Name Description

William Mitchell

Dr. William M. Mitchell, M.D., Ph.D., is Chairman of the Board of the Company. He was appointed Chairman of the Board in February 2016 after serving as a Director since July 1998. Dr. Mitchell is a Professor of Pathology, Microbiology & Immunology at Vanderbilt University School of Medicine and is a board certified physician. Dr. Mitchell earned a M.D. from Vanderbilt and a Ph.D. from Johns Hopkins University, where he served as House Officer in Internal Medicine (Osler Service), followed by a Fellowship at its School of Medicine. Dr. Mitchell has published over 200 papers, reviews and abstracts that relate to the pathogenesis of obligate intracellular pathogens, innate and adaptive immune responses, and liquid biopsy cancer (chromosomal instability) diagnostics. He is the inventor or co-inventor of 14 issued US patents as well as derivative foreign patents. Dr. Mitchell has worked with many professional societies that have included the American Society of Investigative Pathology (ASIP), the International Society for Antiviral Research (ISAR), the American Society of Biochemistry and Molecular Biology (ASBMB), the American Society of Microbiology (ASM), and the American Society of Clinical Oncology (ASCO). Dr. Mitchell is a member of the American Medical Association (AMA). He has served on numerous review committees for the National Institutes of Health (NIH), the Centers for Disease Control (CDC), the European Union (EU), and the College of American Pathology (CAP). He is an independent director of Chronix Biomedical, a genetics based cancer diagnostic company.

Thomas Equels

Mr. Thomas K. Equels Esq., is Executive Vice Chairman, Chief Executive Officer, President, Secretary, & General Counsel of the Company. He was named Chief Executive Officer in February 2016, served as President since August 2015, has been a Director since 2008 and presently serves as our Executive Vice Chairman, Secretary and General Counsel and Litigation Counsel. Mr. Equels previously served as Chief Financial Officer from December 2013 to February 2016. While serving full-time at Hemispherx, Mr. Equels has been the President and Managing Director of the Equels Law Firm based in Miami Florida that focuses on litigation. For over a quarter century, Mr. Equels has represented national and state governments as well as companies in the banking, insurance, aviation, pharmaceutical and construction industries. On numerous occasions, Mr. Equels has been the court appointed receiver to turnaround distressed companies. Mr. Equels received his Juris Doctor degree with high honors from Florida State University. He is a summa cum laude graduate of Troy University and also obtained his Masters' Degree in Management from Troy. He is a member of the Florida Bar Association and the American Bar Association

Adam Pascale

Mr. Adam Pascale CPA, is Chief Financial Officer of the Company. He was named Chief Financial Officer in February 2016, in addition to his current responsibilities as Chief Accounting Officer. Mr. Pascale has been employed with Hemispherx since 1996, with more than two decades of public accounting experience and prior public company experience. He earned a Bachelor of Arts (BA) degree in Accounting and Finance from Rutgers University. Mr. Pascale served for several years as a CPA prior to joining Hemispherx, and is a member of both the American and the Pennsylvania Institutes of Certified Public Accountants.

Wayne Springate

Mr. Wayne Steven Springate is Senior Vice President - Operations of Hemispherx Biopharma Inc. He has served as Senior Vice President of Operations since May 2011 after joining Hemispherx in 2002 as Vice President of Business Development. Mr. Springate came on board when Hemispherx acquired Alferon N Injection® and its New Brunswick, NJ manufacturing facility. He led the consolidation of our Rockville facility to our New Brunswick location as well as coordinated the relocation of manufacturing polymers from South Africa to our production facility in New Brunswick. Currently he is managing a capital improvement budget to enhance our Alferon facility in accordance with current Good Manufacturing Practice (“cGMP”). Previously, Mr. Springate served as President for World Fashion Concepts in New York and oversaw operations at several locations throughout the United States and overseas. Mr. Springate assists the CEO in details of operations on a daily basis and is involved in all aspects of manufacturing, warehouse management, distribution and logistics.

David Strayer

Dr. David R. Strayer, M.D., is Chief Scientific & Medical Officer of the Company. He was appointed Chief Scientific Officer in Feburary 2016 and has acted served as our Medical Director since 1986. Dr. Strayer, based upon this experience, is the foremost medical expert on Ampligen and Alferon in the World. He has served as Professor of Medicine at the Medical College of Pennsylvania and Hahnemann University from 1987 to 1998. Dr. Strayer is Board Certified in Medical Oncology and Internal Medicine with research interests in the fields of cancer and immune system disorders. He has served as principal investigator in studies funded by the Leukemia Society of America, the American Cancer Society, and the National Institutes of Health. Dr. Strayer attended the School of Medicine at the University of California at Los Angeles where he received his M.D. in 1972.

Peter Rodino

Mr. Peter W. Rodino III, Esq., is Executive Director - Governmental Relations, General Counsel of the Company. He was named Executive Director for Governmental Relations and General Counsel in October 2016. Mr. Rodino was appointed a Director of the Company in July 2013 and served in that capacity until his resignation to permit him to serve the Company in this new capacity. While on the Board, he served as Lead Director, Chairman and Financial Expert of the Audit Committee, a member of the Compensation Committee and a member of the Governance and Nomination Committee.appointed Lead Director in September 2015 and has served as a member of to the Board of Directors since July 2013. Mr. Rodino has broad legal, financial, and executive experience. In addition to being President of Rodino Consulting LLC and managing partner at several law firms during his many years as a practicing attorney, he served as Chairman and CEO of Crossroads Health Plan, the first major Health Maintenance Organization in New Jersey. He also has had experience as an investment executive in the securities industry and acted as trustee in numerous Chapter 11 complex corporate reorganizations. For the past 17 years, as founder and president of Rodino Consulting, Mr. Rodino has provided business and government relations consulting services to smaller companies with a focus on helping them develop business plans, implement marketing strategies and acquire investment capital. Mr. Rodino holds a B.S. in Business Administration from Georgetown University and a J.D. degree from Seton Hall University.

Stewart Appelrouth

Mr. Stewart L. Appelrouth is Director of the company. He has served as a member of the Board of Directors since August 2016. Mr. Appelrouth is a certified public accountant and partner at Appelrouth Farah & Co., P.A., Certified Public Accountants and Advisors. Mr. Appelrouth is also a certified forensic accountant and possesses 40 years of experience in Accounting and Consulting. He is a member of or has affiliations with the AICPA, American College of Forensic Examiners, Association of Certified Fraud Examiners, Florida Bar Grievance Committee, Florida Institute of Certified Public Accountants and InfraGard Member, a national information sharing program between the Federal Bureau of Investigation and the private sector. Mr. Appelrouth graduated from Florida State University in 1975 and his Master’s Degree in Finance from Florida International University in 1980.

Charles Jones

Basic Compensation

Name Fiscal Year Total

William Mitchell

1,696,680

Thomas Equels

1,121,850

Adam Pascale

--

Wayne Springate

344,164

David Strayer

314,340

Peter Rodino

--

Stewart Appelrouth

--

Charles Jones

--
As Of  30 Dec 2015